Meeting
2021 ASCO Annual Meeting
HERTHENA-Lung01: A randomized phase 2 study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC.
Authors
Pasi A. Janne
Dana-Farber Cancer Institute, Boston, MA
Pasi A. Janne , Melissa L. Johnson , Yasushi Goto , James Chih-Hsin Yang , Michele Vigliotti , Qian Dong , Yang Qiu , Channing Yu , Helena Alexandra Yu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04619004
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS9139)
DOI
10.1200/JCO.2021.39.15_suppl.TPS9139
Abstract #
TPS9139
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase 1 study of patritumab deruxtecan (HER3-DXd; U3-1402) in combination with osimertinib in patients with advanced EGFR-mutated NSCLC.
First Author: Pasi A. Janne
Poster
2022 ASCO Annual Meeting
Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations.
First Author: Conor Ernst Steuer
Poster
2020 ASCO Virtual Scientific Program
Osimertinib in non-small cell lung cancer (NSCLC) with atypical EGFR activating mutations: A retrospective multicenter study.
First Author: Jingran Ji
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 2, open-label study of amivantamab in patients with previously treated advanced or metastatic gastric or esophageal cancer.
First Author: Daisuke Kotani